Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Niemann-Pick Disease, Type C Clinical Trial

Official title:

Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00668564
• Other study ID #: MT2008-02
• Secondary ID: 0801M25202
• Status: Terminated
• Phase: Phase 2
• First received: April 25, 2008
• Last updated: December 3, 2017
• Start date: March 2008
• Est. completion date: February 2010

Study information

• Verified date: December 2017
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).

Description:

This has been an ongoing area of interest by our group at the Univ. of Minnesota, but this is a new protocol to take the place of several older protocols. While survival has been very good on the prior protocols over the past decade, incomplete engraftment has remained somewhat problematic. Therefore, we have modified the preparative regimen somewhat to increase engraftment by replacing anti-thymocyte globulin (ATG) with Campath-1H, a drug that is more immune suppressive. In addition, we have modified the supportive care regimen. Based on this, we will monitor levels of an anti-oxidant therapy (N-acetylcysteine) and biomarkers of inflammation and oxidative stress for the families that consent to these research studies.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: February 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Mucopolysaccharidosis (MPS) Disorders:

• MPS IH (Hurler syndrome)

• MPS-VI (Maroteaux-Lamy syndrome)

• MPS VII (Sly syndrome).

• Glycoprotein metabolic disorders:

• Alpha mannosidosis

• Fucosidosis

• Aspartylglucosaminuria

• Sphingolipidoses and Recessive Leukodystrophies: Presymptomatic patients with globoid cell leukodystrophy (GLD, also known as Krabbe disease) and metachromatic leukodystrophy (MLD) will be eligible for treatment on this protocol. White matter disease by magnetic resonance imaging (MRI) alone is not an exclusion if the patient is asymptomatic.

• Peroxisomal Disorders: Presymptomatic patients with inherited peroxisomal disorders associated with of very long chain fatty acids (VLCFA) elevation, identified by family history or laboratory testing (including neonatal screening), are eligible for this protocol. White matter disease by MRI alone is not an exclusion if the patient is asymptomatic.

• Other Inherited Diseases of Metabolism:

• Wolman syndrome (acid lipase deficiency)

• Niemann-Pick B patients (sphingomyelin deficiency)

• Niemann-Pick C subtype 2

• Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program: Priority will be as follows, although in circumstances in which timing is of the essence, cord blood grafts may be chosen over an unrelated graft, despite the priority listed above.

• Multidisciplinary Evaluation: Patients will be eligible for transplantation only after they are seen and evaluated by members of the Inherited Metabolic and Storage Disease Program (IMSD) team, and the team has offered transplantation to the patient/family.

Exclusion Criteria:

• Symptomatic patients with peroxisomal or lysosomal disorders are excluded but may be considered for other treatment protocols.

• Major organ dysfunction. Evidence of major organ impairment, including:

• Cardiac: left ventricular ejection fraction <40%

• Renal: serum creatinine >2.5 x normal for age

• Hepatic: total bilirubin >3 x normal, or Alanine transaminase (ALT) > 3 x normal

• Pulmonary: requirement for continuous oxygen supplementation

• Pregnancy

• Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology

• Patients >21 years of age.

Related Conditions & MeSH terms

• Alpha Mannosidosis
• alpha-Mannosidosis
• Aphasia, Primary Progressive
• Aspartylglucosaminuria
• Frontotemporal Dementia
• Fucosidosis
• Hurler's Syndrome
• Krabbe Disease
• Leukodystrophy, Globoid Cell
• Maroteaux-Lamy Syndrome
• Metabolism, Inborn Errors
• Mucopolysaccharidosis I
• Mucopolysaccharidosis VI
• Mucopolysaccharidosis VII
• Niemann-Pick Disease Type B
• Niemann-Pick Disease, Type C
• Niemann-Pick Diseases
• Pick Disease of the Brain
• Sly Syndrome
• Sphingolipidoses
• Syndrome
• Wolman Disease
• Wolman's Disease

Intervention

Procedure:
• Stem Cell Transplantation
The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.

Drug:
• Cyclophosphamide
Days before Transplant Drug Frequency 4 Cyclophosphamide Once, given over 2 hours 3 Cyclophosphamide Once, given over 2 hours 2 Cyclophosphamide Once, given over 2 hours 1 Cyclophosphamide Once, given over 2 hours
• Campath-1H
Days before Transplant Drug Frequency 12 Campath-1H Once, given over 2 hours 11 Campath-1H Once, given over 2 hours 10 Campath-1H Once, given over 2 hours
• Busulfan
Days before Transplant Drug Frequency 9 Busulfan Four times per day 8 Busulfan Four times per day 7 Busulfan Four times per day 6 Busulfan Four times per day

Locations

Country	Name	City	State
United States	University of Minnesota, Fairview	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients Achieving Engraftment	Rate of successful engraftment - patients who achieved and sustained donor engraftment; donor chimerism by day 100 of at least 90% after undergoing hematopoietic stem cell transplantation.	Day 100
Secondary	Overall Survival	Number of patients alive at timepoints.	Day 100, 1 Year, 3 Years